VEGFA and non-small cell lung carcinoma: However, a recent clinical trial in advanced NSCLC patients treated with enzastaurin did not show a consistent change in plasma VEGF levels, but low baseline VEGF levels were associated with longer progression-free survival (Oh et al, 2008).